Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARESTOCAINE HYDROCHLORIDE vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
There is no FDA black box warning for Arestocaine hydrochloride.
None
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARESTOCAINE HYDROCHLORIDE vs ADALAT, answered by our medical review team.
ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARESTOCAINE HYDROCHLORIDE and ADALAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARESTOCAINE HYDROCHLORIDE and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.